Public support for EDCTP

Overview

A broad range of advocacy, research and funding organisations as well as Product Development Partnerships have publicly expressed their support for EDCTP and a second EDCTP programme. The context for this support is usually the urgent appeal for investment in research and development for poverty-related and neglected diseases. These statements are brought together on this page.

Saving Lives and Creating Impact: EU investment in poverty-related neglected diseases

Poverty-Related and Neglected Diseases (PRNDs) are infectious diseases that disproportionally affect the world’s poorest populations. Europe plays a critical role in developing new PRND products. Funding from the European Union (EU), which includes funding from both the European Commission (EC) and Member
States, has increased in recent years and has been essential to bringing these new products to market.

This report Saving Lives and Creating Impact: EU investment in poverty-related neglected diseases by Policy Cures and funded by DSW (Deutsche Stiftung Weltbevölkerung) re-examines the case for EU investment in PRND research and development (R&D). This report assesses the impact of EU funding for PRND R&D, highlighting the return on investment for both developing countries and the EU.

The report concludes that the return on PRND R&D investment to the EU and developing countries could be improved by implementing the following recommendations:

  1. The EU should increase its investments in PRND R&D under Horizon 2020. To develop a broad and sustainable funding base, all Member States should share responsibility for funding PRND R&D, including through funding collaborative mechanisms such as EDCTP and PDPs as well as their own national research institutions.
  2. The EU should retain and foster the distinctive benefits of its approach to funding PRND R&D. EU investment in PRND R&D is distinctive in many positive ways – it focuses on collaboration and partnerships, promotes institutional excellence and capacity building in developing countries and attracts industry participation. Future investment should continue to promote all these aspects. Opportunities to do so include encouraging stronger industry relationships with EDCTP and bringing more European countries
    into this mechanism.
  3. The EU should improve specific aspects of its investment in PRND R&D, to ensure greater efficiency, impact and value. To deliver better value for money, the EU should streamline conditions and processes to ensure the best research candidates are prioritised, including by increasing coordination at all levels, i.e. between Member States; between Member States and the EC (e.g. through pooled funding mechanisms like EDCTP); within Member States, particularly between science & technology and aid agencies; between EU and non-EU partners, including between EU- and U.S.-based PDPs.

To top

Call to EU Leadership on Global Health R&D

Twenty-three non-governmetal organisations working in the field of global health have signed a Call to EU Leadership in global health reseach and development. The organisations urge the European Union to take a leadership rol in global health research and development by:

  • Supporting the recommendation of the WHO-Consultative Expert Working Group on R&D financing and coordination to develop a roadmap for a binding international R&D convention
  • Ensuring the implementation of the recommendations of the 2010 Council Conclusions on the EU role in global health
  • Garanteeing that global health R&D is a priority in Horizon 2020. This includes fully funding the second phase of the EDCTP programme (500M Euro) and committing an additional 500M Euro of the Horizon 2020 Health budget to research necessary to fight poverty-related and neglected diseases outside the scope of EDCTP2.     

The position paper was endorsed by: Action for Global Health; Action Global Health Advocacy Partnership; Afrihealth Optonet Association (Nigeria); DNDi (Drugs for Neglected Diseases initiative); DSW; EATG (European AIDS Treatment Group); EVI (European Vaccine Initiative); FIND (Foundation for Innovative New Diagnostics); Friends of the Global Fund Europe; Global Health Advocates; HAI Europe; International Partnership for Microbicides; MSF Access Campaign; Planeta Salud; Results; Salud por Derecho (Right to Health Foundation); Saules smiltys [TB charity, Lithuania]; Stop AIDS Alliance; Stop TB Lietuva; TB Alert; TBVI; TACD (Transatlantic Consumer Dialogue); UAEM (Universities Allied for Essential Medicines).

To top

Key Recommendations for inclusion in Horizon 2020

A group of global Product Development Partnerships (PDPs) published its Key Recommendations for inclusion in Horizon 2020 of research and innovation regarding neglected diseases. The paper explains and recommends the PDP approach and gives “Specific Recommendations concerning EDCTP2. PDPs strongly support the goal of EDCTP to build partnerships and to support and facilitate clinical trials in Africa. Given the growing significance of EDCTP as an important mechanism for funding and building capacity for global health research, it is timely that its design and scope be revised so that a broader range of PDPs are able to effectively utilize this mechanism.”

The group consists of Aeras (TB vaccine development); DNDi; FIND; IAVI; IPM (International Partnership for Microbicides); MMV; Path catalyst for global health; and the TB Alliance (Global Alliance for TB Drug Development).

To Top

Creating the Tools of Tomorrow: investing in global health R&D

Four organisations involved in development and global health published Creating the Tools of Tomorrow: investing in global health R&D. The fact sheet argues the urgent need to invest in research and development to fight infectious diseases; maternal, infant and child health issues; and nutritional deficiencies. EDCTP is briefly discussed as “example of a successful partnership for product development.” The paper mentions EDCTP’s contribution to the funding of “two ongoing Aeras-sponsored trials of the world’s most clinically advanced tuberculosis vaccine candidates in Africa”.

The organisations that published this appeal to sustain the momentum and continue investment in global health R&D are the Bill & Melinda Gates Foundation, DWS (Deutsche Stiftung Weltbevölkerung, a German development foundation), the Global Health Technologies Coalition (in which 40 non-profit organisations participate), and Policy Cures, an independent research and advisory group in the field of neglected diseases.

To top

Research and Development for Poverty-Related and Neglected Diseases: a priority in the next EU research Framework Programme “Horizon 2020”

More than 30 organisations have advocated that the new European research framework programme, Horizon 2020, prioritises research for poverty related diseases. The position paper Research and Development for Poverty-Related and Neglected Diseases: a priority in the next EU Research Framework Programme “Horizon 2020” was brought to the attention of Members of the European Parliament and the governments of the European Member States. The parties which took this initiative urge the European Union among other things “to ensure sufficient and predictable funding towards EDCTP2” and to consider some changes in its structure.

The position paper was endorsed by: Action for Global Health; Aeras; CBM Severo Ochoa; COHRED; Comité Antisiada de Palencia; CPSS; FIND (Foundation for Innovative New Diagnostics); DNDi (Drugs for Neglected Diseases initiative); DSW; European AIDS Treatment Group; Fundación Cultura de Paz; Fundación Cyca (Inesfly); Global Forum for Health Research; Global Health Advocates; Global Health Europe; IAVI (International Aids Vaccine Initiative); International HIV/AIDS Alliance in Ukraine; International Partnership for Microbicides; Investen Instituto de Salud Carlos III; ISGlobal Barcelona Institute for Global Health; KNCV tuberculosis Foundation; Malaria Consortium; Malaria No More United Kingdom; MMV ((Medicines for Malaria Venture); Path; Planeta Salud; REDVIH; Results; Roll Back Malaria Partnership; Salud por Derecho (Right to Health Foundation); Stop AIDS Alliance; Stop TB; Stop TB Lietuva; TB Alert; TBVI; VIH-DA Associació; World Vision.

To top

Concept for Research Funding Neglected and Poverty-Related Diseases

In July 2011, the German Federal Ministry of Education and Research (BMBF) published a Concept for Research Funding for the Neglected and Poverty-Related Diseases.

It shows a strong German commitment to EDCTP: "Germany’s participation in the European and Developing Countries Clinical Trials Partnership (EDCTP) already represents the main focus of Germany’s involvement in clinical research on HIV/AIDS, malaria and tuberculosis. This commitment will be increased and expanded in coming years." (p. 2)

It contains a clear endorsement of the second EDCTP programme: "The BMBF plans to intensify its involvement in this second programme phase in cooperation with its European and African partners." (p. 18)

To top